Long-term safety of ketoconazole foam, 2% in the treatment of seborrheic dermatitis: results of a phase IV, open-label study.
Abstract | BACKGROUND: OBJECTIVE: To assess the long-term safety of ketoconazole foam, 2%, twice daily, as required. METHODS: A 12-month, open-label, multicenter study. Subjects were evaluated at baseline and at weeks 4, 8, 16, 26, 39, and 52 (or early termination [ET]) for adverse events (AEs), serious AEs (SAEs), target lesion erythema, scaling, and pruritus, as well as Investigator's Static Global Assessment (ISGA) scores. Physical examinations were performed at baseline and at week 52/ET, and laboratory evaluations at baseline and at weeks 8, 26, and 52. A poststudy product-preference questionnaire was completed. RESULTS: Of 500 subjects enrolled, 498 were included in the safety population, and 363 completed the study. Overall, 57% of subjects reported ≥1 AE. Treatment-related AEs occurred in 14% of subjects, including application-site irritation (8%), application-site pain (4%), application-site pruritus (1%), and increased alanine aminotransferase (1%). Seven subjects were withdrawn because of treatment-related AEs. No SAEs (21 in 17 subjects) were considered to be related to study drug. Mean target lesion erythema, scaling, and pruritus scores improved by 2 units from baseline at all study visits; mean ISGA score improved by 1 unit at week 4 and by 2 units at subsequent visits. The foam vehicle was preferred by 67% of subjects. LIMITATIONS: Evaluation of severity was limited to target lesion; no objective measure of adherence. CONCLUSION:
|
Authors | Zoë D Draelos, Steven R Feldman, Victoria Butners, Alessandra B Alió Saenz |
Journal | Journal of drugs in dermatology : JDD
(J Drugs Dermatol)
Vol. 12
Issue 1
Pg. e1-6
(Jan 2013)
ISSN: 1545-9616 [Print] United States |
PMID | 23377341
(Publication Type: Clinical Trial, Phase IV, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antifungal Agents
- Pharmaceutical Vehicles
- Ketoconazole
|
Topics |
- Adolescent
- Adult
- Age Factors
- Aged
- Aged, 80 and over
- Antifungal Agents
(adverse effects, therapeutic use)
- Child
- Chronic Disease
- Dermatitis, Seborrheic
(drug therapy, pathology)
- Endpoint Determination
- Ethnicity
- Female
- Humans
- Ketoconazole
(adverse effects, therapeutic use)
- Male
- Middle Aged
- Patient Compliance
- Patient Preference
- Pharmaceutical Vehicles
- Sample Size
- Sex Factors
- Young Adult
|
|
Join CureHunter, for free Research Interface BASIC access!
Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease.
Find out why thousands of doctors, pharma researchers and patient activists
around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!
|